IL1B and Hepatic steatosis: In vitro treatment of KCs with FFAs (e.g., palmitate) promotes activation and secretion of inflammatory cytokines (e.g., IL-6, TNF, IL-1β) (43) while KC depletion in vivo protects from obesity-driven hepatic steatosis (13).